Systemic gap in drug subsidies leaves low-income pregnant women with fewer treatment options
Pregnant women in Australia are facing an unfair two-tiered system for managing morning sickness, with financial status affecting who can access the full range of modern anti-nausea medications available rather than simply clinical need.
A new study highlights a systemic issue with Australia's Pharmaceutical Benefits Scheme (PBS) that disproportionately affects low-income pregnant women. The research, led by the University of Technology Sydney's Dr. Hannah Jackson, reveals that the PBS's narrow range of approved drugs for morning sickness leaves many women with fewer treatment options.
Ondansetron, despite not officially approved for use in pregnancy, makes up 54% of PBS anti-nausea medication expenditure. This indicates that doctors frequently resort to workarounds to ensure low-income women can afford necessary treatment, creating a form of "Robin Hood" scenario. The study, published in Acta Obstetricia et Gynecologica Scandinavica, calls for expanding the PBS to include more pregnancy-relevant medications, arguing that this would reduce socioeconomic inequalities in treatment access and public spending.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
